Association between the skeletal muscle mass to visceral fat area ratio and metabolic dysfunction‐associated fatty liver disease: A cross‐sectional study of NHANES 2017–2018

Détails bibliographiques
Auteurs principaux:	Zhiliang Mai, Yinfei Chen, Hua Mao, Lisheng Wang
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Journal of Diabetes
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Associations between cuprotosis‐related genes and the spectrum of metabolic dysfunction‐associated fatty liver disease: An exploratory study
par: Hai‐Yang Yuan, et autres
Publié: (2024)

Characterization of brain morphology associated with metabolic dysfunction‐associated steatotic liver disease in the UK Biobank
par: Wenxiao Fan, et autres
Publié: (2025)

Serum bile acid profiles are associated with heart failure with preserved ejection fraction in patients with metabolic dysfunction‐associated fatty liver disease: An exploratory study
par: Xiao‐Dong Zhou, et autres
Publié: (2024)

Coexistence of high visceral fat area and sarcopenia is associated with atherosclerotic markers in old‐old patients with diabetes: A cross‐sectional study
par: Motoya Sato, et autres
Publié: (2024)

G3BP1 , a stress granule core protein, ameliorates metabolic dysfunction‐associated fatty liver disease by attenuating hepatocyte lipid deposition
par: Xingjing Liu, et autres
Publié: (2025)

Long‐term outcomes of metabolic surgery versus medical/lifestyle therapy on metabolic dysfunction‐associated fatty liver disease in adults with obesity and type 2 diabetes
par: Michelle D. Lundholm, et autres
Publié: (2024)

Causal relationship between key genes and metabolic dysfunction‐associated fatty liver disease risk mediated by immune cells: A Mendelian randomization and mediation analysis
par: Gong Feng, et autres
Publié: (2024)

Reduced insulin clearance in paediatric metabolic (dysfunction)‐associated fatty liver disease and its dual role in beta‐cell offload and diabetes risk
par: Li Jiang, et autres
Publié: (2024)

Non‐invasive assessment of hepatic steatosis by ultrasound‐derived fat fraction in individuals at high‐risk for metabolic dysfunction‐associated steatotic liver disease
par: Federica Tavaglione, et autres
Publié: (2024)

Non‐linear relationship between liver fibrosis and femoral neck bone mineral density in metabolic dysfunction‐associated fatty liver disease patients with type 2 diabetes mellitus
par: Jie Tao, et autres
Publié: (2025)

High‐intensity interval training induces lactate dehydrogenase B lactylation to inhibit hepatic lipogenesis to alleviate metabolic dysfunction‐associated fatty liver disease
par: Wenhua Huang, et autres
Publié: (2026)

A nomogram incorporating clinical and laboratory indicators for predicting metabolic dysfunction‐associated fatty liver disease in newly diagnosed type 2 diabetes patients
par: Tingting Li, et autres
Publié: (2025)

Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease
par: Tsung‐Hua Shen, et autres
Publié: (2024)

High estradiol/testosterone ratio increased the risk of metabolic dysfunction‐associated steatotic liver disease in men with type 2 diabetes mellitus
par: Meng‐Han Li, et autres
Publié: (2025)

Elevated small dense low‐density lipoprotein cholesterol to high‐density lipoprotein cholesterol ratio is associated with an increased risk of metabolic dysfunction associated fatty liver disease in Chinese patients with type 2 diabetes mellitus
par: Shouxing Yang, et autres
Publié: (2024)

Sex differences of visceral fat with cardiac structure and function in type 2 diabetes: A cross‐sectional study
par: Chen Rui‐hua, et autres
Publié: (2024)

Non‐invasive diagnosis of metabolic dysfunction‐associated steatotic liver disease: Current status, challenges, and future directions
par: Yuqing Ma, et autres
Publié: (2025)

Glycaemic control metrics and metabolic dysfunction–associated steatotic liver disease in children and adolescents with type 1 diabetes
par: Claudio Maffeis, et autres
Publié: (2024)

Letter to the Editor to “ G3BP1 , a stress granule core protein, ameliorates metabolic dysfunction‐associated fatty liver disease by attenuating hepatocyte lipid deposition”
par: Cyril Sobolewski, et autres
Publié: (2025)

Clinical utility of liver function tests for resolution of metabolic dysfunction‐associated steatotic liver disease after weight loss in the Diabetes Remission Clinical Trial
par: S. V. Zhyzhneuskaya, et autres
Publié: (2024)

Coexistence of high visceral fat area and sarcopenia and atherosclerotic markers in older patients with diabetes: Is there an association?
par: Christian Saleh
Publié: (2024)

An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes
par: Zhuolin Zhou, et autres
Publié: (2025)

Caution in interpreting imaging‐based rankings in network meta‐analyses of metabolic dysfunction–associated steatotic liver disease therapies
par: Seoung Hoon Kim
Publié: (2026)

Donor fat‐to‐muscle ratio and kidney transplant outcomes: A proposition of metabolic memory
par: Youn Kyung Kee, et autres
Publié: (2024)

The prognostic value of metabolic dysfunction‐associated steatotic liver disease in acute myocardial infarction: A propensity score‐matched analysis
par: Gwyneth Kong, et autres
Publié: (2024)

Association between appendicular skeletal muscle mass‐to‐visceral fat area ratio and cardiovascular disease: A cross‐sectional study
par: Zehao Feng, et autres
Publié: (2026)

Modelling and assessment of glucose‐lactate kinetics in youth with overweight, obesity and metabolic dysfunction‐associated steatotic liver disease: A pilot study
par: Jacopo Bonet, et autres
Publié: (2024)

Empagliflozin mitigates metabolic dysfunction‐associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes
par: Sarra Smati, et autres
Publié: (2024)

Metabolic dysfunction‐associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi‐centre cross‐sectional study
par: Michela Vergani, et autres
Publié: (2025)

The Ligustrum lucidum‐derived glycoside specnuezhenide alleviates metabolic‐associated fatty liver disease in mice via modulation of gut microbiota and the PPARα signalling pathway
par: Kai Gao, et autres
Publié: (2026)

Comparative efficacy and safety of pharmacologic therapies for metabolic dysfunction‐associated steatotic liver disease over 24 weeks in reducing liver steatosis and fibrosis: A network meta‐analysis
par: Jiaxin Zhong, et autres
Publié: (2025)

Metabolic dysfunction‐associated steatotic liver disease and cancer risk: A cohort study
par: Yu Peng, et autres
Publié: (2025)

Metabolic dysfunction‐associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes
par: Chloë Aernouts, et autres
Publié: (2024)

Diagnostic accuracy of Agile‐4 score for liver cirrhosis in patients with metabolic dysfunction‐associated steatotic liver disease. A systematic review and meta‐analysis of diagnostic test accuracy studies
par: Konstantinos Malandris, et autres
Publié: (2024)

Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction‐associated steatotic liver disease: A retrospective nationwide claims database study in Japan
par: Mitsuhiro Shikamura, et autres
Publié: (2024)

Association of overweight/obesity and overweight/obesity‐related metabolic dysfunction‐associated steatotic liver disease in young adults with coronary artery calcification later in life
par: Jia‐Jie Wang, et autres
Publié: (2024)

Reply to the comments of Saleh et al. on “Coexistence of high visceral fat area and sarcopenia and atherosclerotic markers in old‐old patients with diabetes: Is there an association?”
par: Motoya Sato, et autres
Publié: (2024)

The depletion of serine beta‐lactamase‐like protein (LACTB) ameliorates metabolic dysfunction–associated steatotic liver disease by reducing ubiquitin‐mediated degradation of carnitine palmitoyltransferase 2
par: Wujiang Shi, et autres
Publié: (2026)

Hepatic steatosis index for prediction of metabolic dysfunction‐associated steatotic liver disease ( MASLD ) among young Indian women with gestational diabetes and normoglycaemia during index pregnancy
par: Alpesh Goyal, et autres
Publié: (2025)

Association of metabolic score for visceral fat with all‐cause mortality, cardiovascular mortality, and cancer mortality: A prospective cohort study
par: Shanshan Jia, et autres
Publié: (2024)

Documents similaires

Documents similaires